BTK and B-cell chronic lymphocytic leukemia: As impaired humoral immunity and increased infection risk resulting from panhypogammaglobulinemia are characteristic of advanced CLL, the effect of BTK inhibition on normal B cell function in CLL may have clinical relevance.